WILMINGTON, MASSACHUSETTS -- (MARKET WIRE) -- November 03, 2006 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan photodynamic therapy (“PDT”) and other treatments for common skin conditions, today reported financial results for the third quarter ended September 30, 2006. Revenue for the quarter was $6.1 million, compared to $2.4 million in the third quarter of 2005. The increase in year over year revenue was driven by a 35% increase in PDT revenues ($3.2 million vs $2.4 million) and the addition of $2.8 million in ‘non-PDT revenue’ associated with the products acquired in the merger with Sirius Laboratories, Inc. (“Sirius”) that closed on March 10, 2006. Revenue for the nine-month period was $17.4 million, versus $8.0 million in the comparable 2005 period. The increase in year to date revenue was driven by a 37% increase in PDT revenue ($10.9 million vs $8.0 million) as well as, $6.5 million in non-PDT revenue.
